Literature DB >> 23251753

Unusual asthma syndromes and their management.

Jaymin B Morjaria1, Jack A Kastelik.   

Abstract

Asthma usually presents with symptoms of wheeze, dyspnoea and cough. However, clinicians should be aware of atypical presentation of this disorder when cough is the main or only symptom in conditions such as cough-variant asthma, nonasthmatic eosinophilic bronchitis and atopic cough. Early diagnosis and treatment of these conditions with inhaled corticosteroids improves symptoms in the majority of patients. Up to 10% of patients with asthma remain poorly controlled in spite of optimal standard therapy. These patients have been encompassed under the term 'treatment-refractory asthma' (TRA), have the greatest morbidity and are responsible for more than 50% of healthcare costs. In this review we discuss investigations, management and pathophysiology of the various phenotypes of atypical presentations of asthma as well as novel biological agents licensed and those that have been reported in clinical trials in terms of their efficacy and safety in TRA.

Entities:  

Keywords:  atopic cough; biologics; cough; eosinophilic bronchitis; monoclonal antibodies; severe asthma

Year:  2011        PMID: 23251753      PMCID: PMC3513887          DOI: 10.1177/2040622311407542

Source DB:  PubMed          Journal:  Ther Adv Chronic Dis        ISSN: 2040-6223            Impact factor:   5.091


  131 in total

Review 1.  Eosinophilic bronchitis - what is it and why is it important?

Authors:  C E Brightling; I D Pavord
Journal:  Clin Exp Allergy       Date:  2000-01       Impact factor: 5.018

2.  Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group.

Authors:  H Milgrom; R B Fick; J Q Su; J D Reimann; R K Bush; M L Watrous; W J Metzger
Journal:  N Engl J Med       Date:  1999-12-23       Impact factor: 91.245

3.  Development of irreversible airflow obstruction in a patient with eosinophilic bronchitis without asthma.

Authors:  C E Brightling; G Woltmann; A J Wardlaw; I D Pavord
Journal:  Eur Respir J       Date:  1999-11       Impact factor: 16.671

4.  A pathogenic triad in chronic cough: asthma, postnasal drip syndrome, and gastroesophageal reflux disease.

Authors:  B C Palombini; C A Villanova; E Araújo; O L Gastal; D C Alt; D P Stolz; C O Palombini
Journal:  Chest       Date:  1999-08       Impact factor: 9.410

5.  Eosinophilic bronchitis is an important cause of chronic cough.

Authors:  C E Brightling; R Ward; K L Goh; A J Wardlaw; I D Pavord
Journal:  Am J Respir Crit Care Med       Date:  1999-08       Impact factor: 21.405

6.  Neutrophilic inflammation in severe persistent asthma.

Authors:  A Jatakanon; C Uasuf; W Maziak; S Lim; K F Chung; P J Barnes
Journal:  Am J Respir Crit Care Med       Date:  1999-11       Impact factor: 21.405

7.  Airway inflammation, airway responsiveness and cough before and after inhaled budesonide in patients with eosinophilic bronchitis.

Authors:  C E Brightling; R Ward; A J Wardlaw; I D Pavord
Journal:  Eur Respir J       Date:  2000-04       Impact factor: 16.671

Review 8.  Anti-T cell strategies in asthma.

Authors:  O M Kon; A B Kay
Journal:  Inflamm Res       Date:  1999-10       Impact factor: 4.575

9.  Eosinophilic tracheobronchitis and airway cough hypersensitivity in chronic non-productive cough.

Authors:  M Fujimura; H Ogawa; M Yasui; T Matsuda
Journal:  Clin Exp Allergy       Date:  2000-01       Impact factor: 5.018

10.  Requirement for IL-13 independently of IL-4 in experimental asthma.

Authors:  G Grünig; M Warnock; A E Wakil; R Venkayya; F Brombacher; D M Rennick; D Sheppard; M Mohrs; D D Donaldson; R M Locksley; D B Corry
Journal:  Science       Date:  1998-12-18       Impact factor: 47.728

View more
  1 in total

1.  lncRNA PCGEM1 strengthens anti-inflammatory and lung protective effects of montelukast sodium in children with cough-variant asthma.

Authors:  Zhenxing Xu; Lingling Meng; Yuejuan Xie; Wei Guo
Journal:  Braz J Med Biol Res       Date:  2020-06-05       Impact factor: 2.590

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.